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Boston, Massachusetts; Salamanca, Spain; and Miami, FloridaObjectives This study sought to examine the frequency of indications for and the immediate and
long-term clinical outcomes of transcatheter closure of patent foramen ovale (PFO).
Background Transcatheter PFO closure is commonly performed for several indications, including
cryptogenic stroke, despite conﬂicting data regarding the efﬁcacy of this intervention.
Methods We report the outcomes of 800 consecutive patients (52% male, 50  14 years of age) who
underwent PFO closure at our institution after multidisciplinary evaluation over a 16-year period.
Results Indications for closure included cryptogenic cerebrovascular event (94%), hypoxemia (2%),
peripheral embolism (3%), and migraine headaches (2%). Procedural success was 99% with effective
closure obtained in 93% of patients. At a mean follow-up of 42.7  33.4 months, 21 patients suffered
a recurrent ischemic neurologic event (12 strokes, and 9 transient ischemic attacks) for an incidence
rate of 0.79 events per 100 person-years and freedom from recurrent events of 91.6% at 10 years.
There was no device-based difference in the rate of recurrent ischemic neurologic events (p ¼ 0.82).
Only Eustachian valve prominence (hazard ratio: 9.04; 95% conﬁdence interval: 2.07 to 39.44; p ¼
0.0034) was associated with recurrent neurologic events.
Conclusions Transcatheter PFO closure is safe and feasible in patients with several clinical indications.
The long-term efﬁcacy of this intervention in patients with paradoxical embolism appears superb in
this observational study. Carefully selected patients with features suggestive of paradoxical embolism
are the most likely to beneﬁt from PFO closure and should be the focus of future investigation. (J Am
Coll Cardiol Intv 2013;6:1176–83) ª 2013 by the American College of Cardiology FoundationFrom the *Cardiology Division, Department of Medicine, Massachusetts General Hospital, Harvard, Medical School, Boston,
Massachusetts; yCardiology Division, University Hospital of Salamanca, Salamanca, Spain; zDivision of Hematology and
Oncology, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts;
xDepartment of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts; and the kDivision
of Cardiology, Aventura Medical Center, Miami, Florida. Dr. Buonanno is an investigator in the PREMIUM migraine trial. All
other authors have reported that they have no relationships relevant to the contents of this paper to disclose. Drs. Inglessis and
Elmariah contributed equally to the manuscript. Dr. Demirjian is deceased.
Manuscript received June 1, 2013; accepted June 21, 2013.
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S , V O L . 6 , N O . 1 1 , 2 0 1 3 Inglessis et al.
N O V E M B E R 2 0 1 3 : 1 1 7 6 – 8 3 Outcomes of PFO Closure
1177The clinical implications of patent foramen ovale (PFO)
have been unclear and have driven substantial debate within
the ﬁeld of cardiovascular medicine. The most commonly
feared consequence of PFO is a paradoxical embolism re-
sulting in a neurologic event or peripheral embolism (1–6),
but PFO has also been associated with the platypnea-
orthodeoxia syndrome, hypoxemia, decompression sickness
in divers, and migraine headaches (3,7–15). Although no
percutaneous transcatheter device is currently approved in
the United States for PFO closure, the off-label use of atrialSee page 1184
Abbreviations
and Acronyms
CI = conﬁdence interval(s)
HR = hazard ratio(s)
PFO = patent foramen ovale
TIA = transient ischemic
attackseptal defect closure devices for PFO closure has been
widespread (16). We and others have shown that trans-
catheter PFO closure is a safe intervention that is associated
with favorable short- and intermediate-term outcomes (17);
however, the efﬁcacy of transcatheter PFO closure has
been questioned due to conﬂicting clinical data (14–21).
In contrast to substantial favorable observational data
(14–17,21), 3 randomized controlled trials assessing PFO
closure for secondary prevention of cryptogenic ischemic
neurologic events each failed to meet their primary efﬁcacy
endpoint (18–20). However, results of secondary and
subgroup analyses favoring PFO closure in addition to several
challenges in trial execution have introduced further uncer-
tainty to the ﬁeld. The present study seeks to report the
long-term clinical outcomes of patients with PFO who
underwent transcatheter closure at theMassachusettsGeneral
Hospital.Methods
Patient population. A total of 800 adult patients under-
went transcatheter PFO closure from January 1, 1995 to
May 20, 2010, at the Massachusetts General Hospital.
All patients were identiﬁed to have a PFO by transthoracic
or transesophageal echocardiography with color Doppler and
agitated saline injection to assess for intracardiac shunting.
Only patients undergoing repeat PFO closure for residual
shunting were excluded from this analysis.
In the event of a suspected paradoxical embolism, PFO
closure was performed only after thorough evaluation and
multidisciplinary discussion. Such patients underwent brain
magnetic resonance imaging, Holter or event monitoring,
assessment of extracranial cerebrovascular disease either by
angiography or Doppler ultrasonography, thrombophilia
testing (proteins C and S, antithrombin III, lupus antico-
agulant, anticardiolipin antibodies, homocysteine, and factor
V Leiden), and pelvic magnetic resonance venography to
screen for May-Thurner anatomy. Patients were also inde-
pendently evaluated by specialists in cardiology, hematology,
vascular medicine, and neurology; they were ultimatelyjointly discussed at a weekly PFO committee meeting.
The committee would consider the appropriateness of
transcatheter closure on the basis of the perceived likelihood
that the clinical event was PFO-related, the risk of recurrent
thromboembolic event, the presence of inciting events such
as prolonged travel, immobility, or hormonal therapy, and
the ability of the patient to receive anticoagulation therapy.
Patients with substantial competing risk factors for recurrent
thromboembolic events, such as atrial ﬁbrillation or ad-
vanced vascular disease, were largely treated conservatively
and not closed.
Echocardiographic assessment. All patients underwent trans-
thoracic and/or transesophageal echocardiographic evaluation
prior to PFO closure. Intracardiac right-to-left shunting
suggestive of PFO was characterized by the appearance
of microbubbles in the left atrium within 3 beats of right
atrial opaciﬁcation at rest or with release of the Valsalva
maneuver. The severity of shunt was categorized as follows:
0¼ none/trace,<3microbubbles in the left atrium; 1¼ small,
indicating the presence of 3 to 9 microbubbles in the left
atrium; 2 ¼ moderate, indicating 10 to 30 microbubbles in
the left atrium after administration of agitated saline; and
3 ¼ large, >30 microbubbles in
the left atrium after administra-
tion of agitated saline (17). Atrial
septal aneurysm was deﬁned as
>10 mm excursion of the aneu-
rysm beyond the plane of the atrial
septum. A hypermobile atrial
septum was deﬁned as hypermo-
bility that did not meet the criteria
for atrial septal aneurysm. Eustachian valve prominence
was prospectively reported at the discretion of the attending
echocardiographer.
Transcatheter PFO closure procedure. PFO were percuta-
neously closed using the Amplatzer Septal Occluder, the
Amplatzer Multifenestrated Septal Occluder “Cribiform”
device (St. Jude Medical, Inc., St. Paul, Minnesota),
CardioSEAL/STARFlex Septal Occlusion system (NMT
Medical, Inc., Boston, Massachusetts), the HELEX Septal
Occluder (W. L. Gore and Associated, Inc., Flagstaff,
Arizona), the Premere PFO closure device (St. Jude Medical,
Inc.), or the Sideris buttoned septal occlusion device (Custom
Medical Devices, Amarillo, Texas) under ﬂuoroscopic and
echocardiographic guidance. Either transesophageal echo-
cardiography or intracardiac echocardiography was used for
intraprocedural guidance. Patients were systemically anti-
coagulated during the PFO closure procedure with intrave-
nous heparinwith a goal activated clotting time of 200 to 220 s.
Patients were also treated with intravenous antibiotics, either
cefazolin or vancomycin, during the procedure and for 24 h
thereafter.
Antithrombotic and anticoagulant therapy. Patients received
aspirin (81 or 325 mg daily) and/or clopidogrel (75 mg daily)
Table 1. Baseline Characteristics (N ¼ 800)
Age, yrs 50  14
Male 418 (52)
Race
White 746 (93)
Black 16 (2)
Hispanic 29 (4)
Asian 9 (1)
Hypertension 254 (31)
Dyslipidemia 276 (35)
Diabetes 48 (6)
Atrial ﬁbrillation 9 (1)
Smoking
Current 75 (9)
Former 201 (25)
Family history of CVD 82 (10)
Migraine headaches 114 (14)
Deep vein thrombosis 10 (1)
May-Thurner anatomy 88 (11)
Hypercoagulable state
Antithrombin III deﬁciency 17 (2)
Protein S deﬁciency 30 (4)
Protein C deﬁciency 7 (1)
Antiphospholipid syndrome 83 (10)
Prothrombin gene mutation 22 (3)
Factor V Leiden 27 (3)
Lipoprotein (a) 78 (10)
HIT 3 (0)
Indications for PFO Closure
Cerebrovascular events
Stroke 564 (71)
TIA 131 (16)
Multiple events 54 (7)
Hypoxemia 18 (2)
Peripheral embolism* 22 (3)
Migraine headaches 12 (2)
Other 2 (0)
PFO Anatomic Features
Direction of shunt
Right to left 694 (87)
Left to right 55 (7)
Bi-directional 51 (6)
Shunt condition
Rest only 119 (15)
Valsalva only 232 (29)
Both 449 (56)
Interatrial septal mobility
Atrial septal aneurysm 203 (25)
Hypermobility 139 (17)
Eustachian valve 11 (1)
Values are mean  SD or n (%). *3 patients suffered peripheral emboli and stroke.
CVD ¼ cardiovascular disease; HIT ¼ heparin-induced thrombocytopenia; PFO ¼ patent
foramen ovale; TIA ¼ transient ischemic attack.
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1178at the discretion of the operator. Patients requiring short- or
long-term anticoagulation with warfarin for other causes,
such as deep venous thrombosis or pulmonary embolism,
were maintained on heparin or low molecular weight
heparin while undergoing warfarin loading. Patients with a
hypercoagulable state, a single thromboembolic event, and
a reversible risk factor for clotting were anticoagulated with
warfarin for 3 months after PFO closure and then switched
to aspirin therapy. Those with 2 or more thromboembolic
events and thrombophilia were prescribed life-long warfarin
anticoagulation.
Clinical and echocardiographic follow-up. All patients
received a transthoracic echocardiogram after closure and
prior to hospital discharge. Patients were then seen in
follow-up at 4 to 6 weeks, 6 months, and annually for
5 years after PFO closure almost uniformly by the inter-
ventional cardiologist. Transthoracic echocardiography was
performed at each visit to assess for residual shunt or other
device-related abnormality. Patients with any recurrent
neurologic symptoms underwent neurological evaluation by
a specialist, and when necessary, the appropriate neurologic
imaging study. For the purpose of this study, attempts were
made to contact patients no longer being followed by our
practice by phone or electronic medical records were
reviewed to identify clinical events. The Massachusetts
General Hospital panel of the Partners Human Research
Committee approved all research activities.
Statistical analysis. Patient characteristics, including demo-
graphics, medical history, imaging and serologic test results,
and procedural data were retrospectively collected. Data are
presented either as mean  SD or median (interquartile
range). Between-group comparisons were made using Fisher
exact test for categorical variables or unpaired Student t test
for continuous variables. Because of the low event rate,
multivariable regression analyses were not conducted.
Kaplan-Meier survival analysis was used to assess the
absolute risk of events after transcatheter PFO closure and
between-group comparisons made using the log-rank test.
All tests were 2-tailed with signiﬁcance accepted at the
p < 0.05. Statistical analyses were performed with SAS
(version 9.2, SAS Institute, Inc., Cary, North Carolina) and
JMP (version, 9, SAS Institute, Inc.).
Results
Patient characteristics. A total of 800 patients were included
in this analysis, with a mean age of 50  14 years. The
cohort was 52% male and 93% white in race (Table 1). Due
to our selection process for transcatheter PFO closure, the
frequency of cardiovascular risk factors was relatively low
with hypertension present in 245 (31%), dyslipidemia in
276 (35%), diabetes in 48 (6%), and current smoking in
75 (9%) patients. A hypercoagulable state was identiﬁed
in 227 (28%) patients. Antiphospholipid syndrome andlipoprotein(a) were the most frequent, identiﬁed in 83 (10%)
and 78 (10%) patients, respectively. May-Thurner anatomy
was documented in 85 (11%) patients.
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1179Transcatheter PFO closure was performed predominantly
in patients who had suffered cerebrovascular event(s) felt to
be due to a paradoxical embolism (Table 1). Of these 749
patients with neurologic events, 564 experienced a stroke,
131 a transient ischemic attack (TIA), and 54 multiple
neurologic events. Closure of PFO was also performed for
hypoxemia in 18 (2%) patients, peripheral embolic events in
22 (3%), and migraine headaches in 12 (2%). Peripheral
embolic events, deﬁned as emboli to the coronary, renal,
splenic, and retinal arteries, occurred concurrently with
a neurologic event in 3 patients. Patients who underwent
transcatheter PFO closure solely for migraine headaches
were treated within clinical trials.
The majority of patients had right-to-left shunting docu-
mented on echocardiographic assessment (87%), although
some patients possessed PFO that were stretched open and
allowed for either bidirectional (6%) or left-to-right shunt-
ing (7%) (Table 1). An atrial septal aneurysm was identiﬁed
in 203 (25%) patients, hypermobile atrial septum in 139
(17%), and a prominent Eustachian valve in 11 (1%) patients.
Procedural outcomes. Of 800 patients, 794 (99%) under-
went successful transcatheter PFO closure, one of which
required multiple devices. Effective closure was obtained in
737 (93%). Of these, 303 (38%) patients received the
Amplatzer Cribiform device, 178 (22%) the Amplatzer
Atrial Septal Occluder, 47 (6%) the Gore Helex Septal
Occluder, 228 (29%) the Cardioseal or STARFlex Occlu-
sion System, 35 (4%) the Sideris buttoned septal occlusion
device, and 2 (0%) the Premere Septal Occluder. We found
no signiﬁcant difference in the rate of effective PFO closure
among devices (p ¼ 0.17) (Table 2). In 6 patients, trans-
catheter PFO closure was unsuccessful. A PFO could not be
identiﬁed in 2 of these patients. Anatomic features
precluded safe device deployment in 3 patients. The last
patient suffered damage to the tricuspid valve during
retrieval of an embolized device. The procedure was conse-
quently aborted, and the patient referred for surgical
tricuspid valve repair and PFO closure.Table 2. Frequency of Atrial Septal Occlusion Device Use
Total
Effective Clos
None/Trace
Overall 794* 677 (85)
Amplatzer Cribiform 303 (38) 258 (85)
Amplatzer ASO 178 (22) 151 (85)
Gore Helex 47 (6) 38 (81)
Cardioseal/STARFlex 228 (29) 200 (88)
Sideris 35 (4) 29 (83)
Premere 2 (0) 1 (50)
Values are n or n (%). *One patient received multiple devices.
ASO ¼ atrial septal occluder.One procedural death occurred due an aortic dissection
and tamponade. Four additional patients experienced tam-
ponade. Device embolization occurred in 4 patients, 1 of
which required surgery as previously described. A procedural
TIA occurred in 1 patient and a deep venous thrombosis in
another (Table 3).
Long-term clinical outcomes. Over a mean follow-up of
42.7  33.4 months (median: 37.1 months, interquartile
range: 16.2 to 59.9 months; 2,666 person-years), a recurrent
ischemic cerebrovascular event occurred in 21 (2.8%) patients,
12 (1.6%) of which were strokes and 9 (1.2%) were TIA
(Table 3). Thus, the cumulative incidence rate of recurrent
cerebrovascular events (ischemic stroke or TIA) was 0.79
events per 100 person-years. When limited solely to patients
referred for ischemic stroke or multiple neurologic events,
7 (1.1%) and 10 (1.6%) patients experienced a recurrent TIA
and stroke, respectively (0.79 events per 100 person-years).
At 5- and 10-year follow-up, 96.7% and 91.5% of patients,
respectively, were free of recurrent ischemic neurologic events
(Fig. 1A). Freedom from recurrent ischemic neurologic
events, procedural or neurologic death was comparably high
(Fig. 1B). In exploratory analyses, we found that only the
detection of a Eustachian valve on transthoracic echocardi-
ography (hazard ratio [HR]: 9.04; 95% conﬁdence interval
[CI]: 2.07 to 39.44; p < 0.0034) (Table 4) was signiﬁcantly
associated with the occurrence of cerebrovascular event after
PFO closure. Notably, the 3 patients with prominent
Eustachian valves who suffered a recurrent event had
persistent residual shunt after PFO closure. There was no
signiﬁcant difference in the rate of neurologic events between
closure devices (log-rank p ¼ 0.82) (Fig. 1C).
Reintervention was performed in 38 (5%) patients for
substantial persistent shunt in 3 patients, concomitant atrial
septal defect in 2 patients, and device embolization in 3
patients (Table 3). Of these 38 patients, 4 underwent
surgical reintervention. The rate of reintervention was 5.7%
at 5 years and 9.3% at 10 years (Fig. 2). Rates of reinter-
vention signiﬁcantly differed by device type with increasedand Associated Residual Shunting
Shunt Severity
p Value
ure
Mild Moderate Severe
59 (7) 27 (3) 30 (4)
20 (7) 8 (3) 17 (6) 0.17
13 (7) 10 (6) 4 (2)
3 (6) 3 (6) 3 (6)
18 (8) 6 (3) 4 (2)
4 (11) 0 (0) 2 (6)
1 (50) 0 (0) 0 (0)
Table 3. Short- and Long-Term Outcomes After Transcatheter PFO Closure
Procedural success 793 (99)
30-day outcomes
Death 0.1 (1/793)
Stroke 0.0 (0/793)
Recurrent 0.0 (0/749)
De novo 0.0 (0/749)
TIA 0.1 (1/793)
Recurrent 0.1 (1/749)
De novo 0.0 (0/44)
Device embolization 0.5 (4/793)
Tamponade 0.6 (5/793)
DVT 0.1 (1/793)
Long-term outcomes
Neurologic death 0.5 (4/793)
Stroke 1.5 (12/793)
Recurrent 1.6 (12/749)
De novo 0.0 (0/44)
TIA 1.2 (10/793)
Recurrent 1.2 (9/749)
De novo 2.3 (1/44)
Redo 5.0 (38/793)
Transcatheter 4.0 (34/793)
Surgical 0.5 (4/793)
DVT ¼ deep venous thrombosis; other abbreviations as in Table 1.
Figure 1. Long-Term Clinical Outcomes After Transcatheter PFO Closure
Kaplan-Meier curves depict the probability of freedom from recurrent
ischemic neurologic events (A) within subjects with previous cryptogenic
stroke (B). Probabilities for freedom from recurrent ischemic neurologic
events are depicted at 5- and 10-year follow-up. Stratiﬁcation by device type
revealed no signiﬁcant difference in the rates of recurrent ischemic neurologic
events between the closure devices (log-rank p ¼ 0.82) (C). ASO ¼ atrial septal
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1180need of redo procedures with the Gore Helex device, many
of which were early generation devices, and with the Sideris
device (p ¼ 0.006) (Table 5).
Four patients died of neurologic causes in addition to the
previously described procedural death (Table 3). One patient
suffered a stroke and died within 2 months of PFO closure.
The patient was found to have a left ventricular thrombus
and marantic endocarditis in the setting of adenocarcinoma
of the lung. Another patient died of a stroke approximately
1 year after PFO closure in the setting of advanced lung
cancer. A third patient suffered a subarachnoid hemorrhage.
The last patient presented with a hemorrhagic stroke.occluder; PFO ¼ patent foramen ovale.Discussion
The present study adds to substantial evidence that trans-
catheter closure of PFO is a feasible and safe technique
(13–17,22–24). We add to the existing literature by estab-
lishing within a large and diverse cohort of patients the
excellent long-term outcomes following transcatheter PFO
closure and the breadth and relative frequency of indications
for which patients are referred for this controversial proce-
dure. Secondary prevention for cryptogenic neurologic
events in patients found to have a PFO is overwhelmingly
the most common reason for PFO closure, although the
technique is considered for patients with peripheral emboli,
migraine headaches, and hypoxemia as well.The efﬁcacy of transcatheter PFO closure, however,
remains quite controversial, especially in regard to secondary
stroke prevention (25,26). Considerable evidence from
a multitude of small observational studies suggest superb
preventative efﬁcacy of PFO closure for recurrent events.
Two recent meta-analyses reviewed data from approximately
50 observational studies including almost 9,000 patients
(16,21). Both studies found the cumulative rate of recurrent
stroke or TIA to be 0.8 events per 100 person-years with
PFO closure versus approximately 5 events per 100 person-
years with medical therapy. These results are comparable to
our results (0.79 events per 100 person-years) as well as
Table 5. Rates of Redo Transcatheter PFO Closure by
Device Type (N ¼ 793)
Overall 38 (5.0) p ¼ 0.006
Amplatzer Cribiform 9 (3.0)
Amplatzer ASD 9 (5.1)
Gore Helex 6 (12.8)
Cardioseal/STARFlex 9 (4.0)
Sideris 5 (14.3)
Premere 0 (0.0)
Values are n (%) with percentage within device type.
ASD ¼ atrial septal defect; PFO ¼ patent foramen ovale.
Table 4. Unadjusted Relationship Between Clinical Factors and Ischemic
Cerebrovascular Events After Transcatheter PFO Closure
Hazard
Ratio
95% Conﬁdence
Interval p Value
Age, yrs 1.02 0.98–1.05 0.35
Male 2.21 0.84–5.80 0.11
Hypertension 2.08 0.86–5.04 0.11
Dyslipidemia 1.69 0.70–4.10 0.24
Diabetes 1.45 0.96–10.95 0.72
Smoking status
None Referent
Current 0.93 0.20–4.48 0.93
Former 1.87 0.72–4.86 0.2
Family history of CVD 0.36 0.05–2.69 0.32
Migraine headaches 1.28 0.29–5.71 0.75
Hypercoagulable state 1.79 0.73–4.39 0.2
PFO anatomic features
Direction of shunt
Right to left Referent
Left to right 2.11 0.61–7.36 0.24
Bi-directional 1.58 0.36–6.98 0.55
Shunt condition
Rest only Referent
Valsalva only 0.54 0.14–2.06 0.37
Both 0.88 0.28–2.78 0.82
Interatrial septal mobility
Atrial septal aneurysm 0.59 0.17–2.02 0.4
Hypermobility 0.72 0.21–2.44 0.59
Eustachian valve 9.04 2.07–39.44 0.0034
Residual shunt severity
None/Trace Referent
Mild 3.16 0.92–10.87 0.07
Moderate None
Severe None
Hazard ratios could not be calculated for May-Thurner or atrial ﬁbrillation due to lack of events.
Abbreviations as in Table 1.
Figure 2. Freedom From Reintervention
Kaplan-Meier curve depicts the probability of freedom from reintervention
after transcatheter patent foramen ovale closure. Probabilities for freedom
from reintervention are depicted at 5- and 10-year follow-up.
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1181those from the recently reported RESPECT (Randomized
Evaluation of Recurrent Stroke Comparing PFO Closure
to Established Current Standard of Care Treatment) trial
(0.66 events per 100 person-years) and PC (Percutaneous
versus Medical Treatment in Patients with Cryptogenic
Embolism) trial (1.06 events per 100 person-years), but are
in stark contrast to results of the CLOSURE I (Evaluation
of the STARFlex Septal Closure System in Patients with
a Stroke and/or Transient Ischemic Attack due to Presumed
Paradoxical Embolism through a Patent Foramen Ovale)
trial (2.6 events per 100 person-years) (18–20).
Several factors have been hypothesized to account for the
high event rates in the CLOSURE I trial (16,25,27). First,
the CLOSURE I trial exclusively used the STARFlex Septal
Closure System for PFO closure. This device, which is no
longer in production, has been associated with higher rates
of atrial ﬁbrillation and in situ thrombosis than other atrialseptum occlusion devices (28,29). Whereas such differences
may lead to higher event rates with the STARFlex device,
our experience suggests no such difference for recurrent
neurovascular events. However, it is notable that we ob-
tained 96% effective closure with the NMT Medical
devices compared with only 86% effective closure in the
CLOSURE I trial. The greater likelihood of effective
closure in our hands may simply be due to our ability to
choose the best device for a given patient’s PFO anatomy,
a freedom that is not available with clinical trials. Alterna-
tively, our extensive experience with the NMT Medical
devices in 29% (228 of 800) of cases may have contributed to
the favorable results. Regardless, such a high prevalence of
residual shunt within CLOSURE I may contribute to the
relatively high event rate observed in the closure group
within the trial. Second, of the 23 patients with recurrent
cerebrovascular events in the device arm of the CLOSURE I
trial, 20 (87%) were felt not to be due to a PFO-mediated
paradoxical embolism. Although some of these recurrent
events were device- or procedure-related, the presence of
subcortical lacunar infarctions, aortic arch atheroma, and
vasculitis in many of these trial participants suggest that
rigorous attempts to exclude patients with alternative causes
of stroke were unsuccessful. Third, evidence is emerging
that the diagnosis of TIA within the CLOSURE I trial was
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1182nonspeciﬁc and possibly represented alternate clinical entities
(30). Thus, the use of previous TIA as an inclusion criterion
and within the primary endpoint likely contaminated
both the study population and endpoint determination,
making it more difﬁcult to demonstrate efﬁcacy of PFO
closure.
Similar challenges have plagued the RESPECT and PC
trials and might have contributed to their failures to meet
primary efﬁcacy endpoints (19,20). Despite demonstrating
large point estimates for relative risk reduction of recurrent
ischemic strokes, both trials suffered from low event rates,
patient crossover, difﬁcult study recruitment, and under-
powered analyses. The widespread availability of off-label
atrial septal defect closure devices for PFO closure likely
contributed to each of these issues by providing a treatment
option for high-risk patients outside of clinical trials and for
those assigned to medical therapy within trials (19,20,31).
As opposed to the CLOSURE I and PC trials, the
RESPECT trial did not use TIA as an inclusion criterion or
clinical endpoint and mandated neuroradiographic conﬁr-
mation of clinical events (18–20). With such stringent
criteria, Carroll et al. (19) demonstrated a large, although
not signiﬁcant, 51% reduction in the primary composite
endpoint of nonfatal or fatal ischemic stroke or early death
(HR: 0.49; 95% CI: 0.22 to 1.11) within the intention-
to-treat cohort. Notably, 3 recurrent strokes in the device
arm of the trial occurred in patients that had not received
transcatheter PFO closure; evaluation of the as-treated
cohort demonstrated a marked reduction in the risk of re-
current ischemic neurologic events with PFO closure (HR:
0.27; 95% CI: 0.10 to 0.75; p ¼ 0.007) (19). An important
lesson from both RESPECT and PC was that the trend
toward beneﬁt with PFO closure was not apparent within
the ﬁrst 2 years after randomization (19,20). The negative
results in CLOSURE I may consequently be in part due to
a short follow-up period (18).
We suspect that the low rate of recurrent events observed
here is at least partly due to our efforts to identify those
patients likely to have suffered a PFO-mediated event.
We subject all patients with a suspected paradoxical embo-
lism to independent evaluation by cardiology, neurology, and
hematology, and by vascular medicine in the event of a deep
venous thrombosis or May-Thurner. On completion of an
extensive evaluation, a decision for or against PFO closure is
jointly made by the specialists largely on the basis of the
likelihood that the index event was PFO-related. This process
has led to denial for PFO closure in approximately 20% to
25% of referred patients, and its success is evident in the low
prevalence of cardiovascular risk factors within our study
cohort (only 6% with diabetes mellitus and 9% smokers).
We found that the detection of a prominent Eustachian
valve on transthoracic echocardiography signiﬁcant predicts
recurrent events. Limited data exist regarding the risk
attributable to a prominent Eustachian valve with PFO(32,33). Rigatelli et al. (32) demonstrated a markedly el-
evated risk of recurrent paradoxical embolisms with prom-
inent Eustachian valve or Chiari network (odds ratio: 7.8;
95% CI: 4.1 to 15; p < 0.001) versus PFO alone. A pro-
minent Eustachian valve was identiﬁed in approximately
40% of patients by intracardiac echocardiography in the
study, compared with only 10 (1%) patients here. We
suspect that differences in the sensitivity of echocardio-
graphic techniques led to this discrepancy. In fact, Rigatelli
et al. (32) report less frequent detection of the Eustachian
valve by transesophageal echocardiography. These data
suggest that only the largest Eustachian valves are likely to
be detected by transthoracic echocardiography and that this
anatomic feature may identify those PFO patients at greatest
risk of paradoxical embolism. The impact of this anatomic
variant after PFO closure logically should depend on the
presence of residual shunt. Here, all patients with prominent
Eustachian valves that suffered a recurrent event also had
residual shunting across the interatrial septum.
Study limitations. This is a retrospective study of highly
selected patients that may differ from those in other pub-
lished series and randomized trials. In addition, a small
number of recurrent events after PFO closure limited our
ability to identify predictive variables. In this regard, our
analyses identifying Eustachian valve prominence and re-
sidual shunt severity as predictors of neurologic events
should be considered hypothesis-generating and will need
conﬁrmation. Furthermore, Eustachian valve prominence
was deﬁned and reported at the discretion of the attending
echocardiographer during routine clinical care. Future
studies using strict deﬁnitions are needed to assess the
clinical impact of this anatomic variant. Whereas our clin-
ical follow-up was comparable to that described in recent
clinical trials, we did not implement systematic methods
of screening for atrial ﬁbrillation or recurrent neurologic
events after PFO closure. Patients were routinely referred
for neurologic assessment for new or recurrent neurologic
symptoms, but this was performed at the discretion of the
interventional cardiologist. Lastly, we do not currently
possess formal clinical assessments of migraine severity
after PFO closure.
Conclusions
Transcatheter closure of PFO is a safe and feasible therapy
for patients with PFO. Consistent with evidence from recent
randomized controlled trials, the recurrence rate for is-
chemic neurologic events is remarkably low after PFO
closure. Carefully selected patients with features suggestive
of paradoxical embolism are the most likely to beneﬁt from
PFO closure and should be the focus of future investiga-
tions. In addition, our analysis suggests Eustachian valve
prominence is a signiﬁcant predictor of recurrent embolic
events after PFO closure. Further efforts are needed to
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S , V O L . 6 , N O . 1 1 , 2 0 1 3 Inglessis et al.
N O V E M B E R 2 0 1 3 : 1 1 7 6 – 8 3 Outcomes of PFO Closure
1183conﬁrm these ﬁndings and to deﬁnitively establish the
clinical role of PFO closure.
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